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ABSTRACT 
Aims 
The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was developed for the World 
Health Organization (WHO) by an international group of substance abuse researchers to detect 
psychoactive substance use and related problems in primary care patients. This report describes the new 
instrument as well as a study of its reliability and feasibility. 
Setting 
The study was conducted at participating sites in Australia, Brazil, Ireland, India, Israel, the Palestinian 
Territories, Puerto Rico, the United Kingdom and Zimbabwe. Sixty per cent of the sample was recruited 
from alcohol and drug abuse treatment facilities; the remainder was drawn from general medical settings 
and psychiatric facilities. 
Methods 
The study was concerned primarily with test item reliability, using a simple test–retest procedure to 
determine whether subjects would respond consistently to the same items when presented in an interview 
format on two different occasions. Qualitative and quantitative data were also collected to evaluate the 
feasibility of the screening items and rating format. 
Participants 
A total of 236 volunteer participants completed test and retest interviews at nine collaborating sites. Slightly 
over half of the sample (53.6%) was male. The mean age of the sample was 34 years and they had 
completed, on average, 10 years of education. 
Results 
The average test–retest reliability coefficients (kappas) ranged from a high of 0.90 (consistency of reporting 
'ever' use of substance) to a low of 0.58 (regretted what was done under influence of substance). The 
average kappas for substance classes ranged from 0.61 for sedatives to 0.78 for opioids. In general, the 
reliabilities were in the range of good to excellent, with the following items demonstrating the highest 
kappas across all drug classes: use in the last 3 months, preoccupied with drug use, concern expressed by 
others, troubled by problems related to drug use, intravenous drug use. Qualitative data collected at the end 
of the retest interview suggested that the questions were not difficult to answer and were consistent with 
patients' expectations for a health interview. The data were used to guide the selection of a smaller set of 
items that can serve as the basis for more extensive validation research. 
Conclusion 
The ASSIST items are reliable and feasible to use as part of an international screening test. Further 
evaluation of the screening test should be conducted. 
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INTRODUCTION 
According to the United Nations Drug Control Programme (UNDCP 1997), illicit drug consumption 
has increased throughout the world in recent years, as estimated from emergency room visits, drug-
related mortality reports and arrests of drug users. Based on unofficial UNDCP estimates, the annual 
global prevalence of illicit drug consumption is in the range of 3–4% of the world population, which is 
far below the estimated consumption of the two primarily legal substances, alcohol (50%) and 
tobacco (20%), but nevertheless of sufficient magnitude to warrant a public health approach to early 
intervention. A key ingredient of a public health approach is the availability of a reliable and valid 
screening test. 
The development of any screening test on an international level must take into account the diverse 
nature of psychoactive substances and of the users themselves. Much has been learned from recent 
research about screening for substance abuse, and these findings have provided a sound empirical 
basis for the design of a new screening test (McPherson & Hersch 2000; Babor 2002). Two different 
approaches have been developed to screen for drug abuse: self-report procedures and biochemical 
tests. The first, exemplified by the Drug Abuse Screening Test (DAST, Skinner 1982), consists of 
direct questions about substance use and related problems. Another self-report screening approach, 
illustrated by the MacAndrew Alcoholism Scale (MacAndrew 1965), consists of indirect questions that 
measure personality traits associated with substance misuse. A variation on the use of direct 
screening questions focusing on specific substances is the use of conjoint screening items, which 
inquire simultaneously about alcohol and drugs. One such instrument is the CAGE alcoholism 
screening test adapted to include drugs (CAGE-AID, Brown & Rounds 1995). 
A second type of screening method for drug abuse is biological tests. Drug screening through such 
methods as urinalysis, hair testing and saliva tests, when performed by someone with proper training, 
is often the quickest, most accurate way to detect recent drug use (Wolff et al. 1999). 
The available self-report screening tests have a number of limitations from an international 
perspective (Babor 2002). First, most tests have been developed and validated in the United States, 
with little evidence that they are sensitive or specific in other cultures. Secondly, many of these tests 
have not been subject to extensive validation research, and several have not been evaluated 
favorably. Thirdly, most of the adult screening tests have been designed for case finding, not to 
identify risk factors. These tests typically avoid direct questions about specific drugs, focusing instead 
on the experience of problems associated with any drug use in the past. Such an approach may be 
susceptible to imprecision and response bias. Fourthly, subtle or disguised screening tests do not 
appear to be sufficiently sensitive to identify active cases, although they may be useful in screening 
for risk factors. Finally, biological screening methods also have limitations (Wolff et al. 1999), such as 
the problems of handling body fluids and the need for scrupulous hygienic procedures. Cost, 
invasiveness, lack of sensitivity and other problems limit the usefulness of biological measures as a 
sole approach to screening, especially in developing countries. 
Based on similar considerations, a critical review of current drug abuse screening techniques (US 
Preventive Services Task Force 1998) concluded that there is insufficient evidence to recommend for 
or against routine screening using currently available, standardized self-report questionnaires or 
biologial assays. Given the prevalence and consequences of drug use throughout the world, it 
appears that there is a need for an international screening test for drug abuse that is reliable, valid, 
flexible, comprehensive and inexpensive. Further work is needed therefore in the development and 
validation of accurate screening instruments, especially instruments suitable for use in primary care in 
areas of the world where drug abuse is prevalent but difficult to detect. To address this need, the 
Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was developed recently for 
the World Health Organization (WHO) by an international group of substance abuse researchers for 
field testing in representative member states in different parts of the world. This report describes the 
results of an international study to test the feasibility and reliability of the new screening test. 
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METHODS 
Working in close collaboration with the WHO Department of Mental Health and Substance 
Dependence, the study was conducted at participating sites in Australia, Brazil, India, Ireland, Israel, 
the United Kingdom, Zimbabwe, the Palestinian Territories and Puerto Rico, a territory of the United 
States. The centers were chosen for their ability to provide access to individuals with different 
substance use patterns. The study was conducted in two stages. The first stage was devoted to 
planning and instrument development. The second stage involved a test–retest exercise and the 
evaluation of the test's feasibility. 
Planning and development of ASSIST 1.0 
Ideally, an international screening test should be adaptable to different cultures, languages and 
settings. It should be flexible enough to identify different substances and different patterns of 
substance use. It should also be capable of serving different purposes, such as case finding as well 
as screening for risk factors. To meet these standards, an international group of substance abuse 
researchers was convened to design a preliminary screening procedure that could be subject to 
testing for reliability and feasibility. Based on a critical review of the literature in screening for drug 
abuse (Babor 2002), the group developed ASSIST 1.0 according to the following guidelines: (1) 
simple instructions that explain the purpose and the nature of the screening questions; (2) the 
inclusion of questions about alcohol and tobacco in order to present the drug items in the context of a 
more general health and lifestyle screening interview; (3) the use of specific drug classes that allow 
differentiation across the full range of abuse liability and dependence potential associated with 
different types of psychoactive substances; and (4) direct questions about the current and past use of 
each substance, as well as problems and dependence symptoms associated with substance use. 
After compiling a comprehensive inventory of test items and response formats that had been used in 
previous interviews and questionnaires, candidate items were constructed for each of the proposed 
content domains. The 12 items selected by consensus for initial evaluation provided ample coverage 
of the content domains considered most relevant to screening: life-time and recent substance use, 
dependence symptoms, substance-related problems and intravenous use. It was decided to include 
alcohol and tobacco products among the substance classes in order to integrate drug screening with 
substances that have achieved greater acceptance in primary care as targets of screening programs. 
Substances other than tobacco and alcohol were differentiated into eight drug classes (rather than 
combining them into a single drug category). This was considered important because of the wide 
variability among these substances in abuse liability and dependence potential. 
ASSIST 1.0 began with an initial screening item that asked about life-time use of commonly used 
substances within the following 10 categories: tobacco products, alcoholic beverages, cannabis, 
cocaine, stimulants, inhalants, sedatives/hypnotics, hallucinogens, opioids and 'other drugs.' If the 
respondent reported no psychoactive substance use, the interview was terminated. If the respondent 
admitted to life-time use of one or more substances, the remaining questions were asked only for 
those substances endorsed in the initial screening question. The 11 additional questions were 
selected from a large pool of items that had been used in previously developed scales to measure the 
frequency of substance use, dependence symptoms, substance-related problems, and injection drug 
use. It was expected that a smaller number of items would be selected for inclusion in the revised 
ASSIST interview upon completion of the reliability study. 
Following the question about life-time use, the second question asked about drug use during the 'past 
3 months'. The drug classes in this question were rated on a five-point frequency scale ranging from 
'never' (in the past three months) to 'daily'. This question provided critical information about the 
substances most relevant to the respondent's current health status. 
If none of the substances had been used in the past 3 months, the interviewer skipped to questions 
9–12 about problems and use patterns that occurred prior to the past 3 months. These questions 
inquired about a past history of harmful use or dependence that may increase the risk of future 
problems even in the absence of current use. 
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If any substance was used once or more during the past 3 months, the remaining questions were 
asked. Question 3 asked about preoccupation with the substance or substances used in the past 3 
months. This was intended as a measure of the salience of substance use, an indicator of 
psychological dependence. Question 4 asked about worry or concern about substance use, a 
possible sign of impaired control. Question 5 queried about problems with family, work or school. This 
is a measure of harmful use. Question 6 dealt with inability to manage routine role obligations, such 
as care of children or employment responsibilities. This was another measure of salience of drug use. 
Question 7 examined guilt associated with drug use. Question 8 asked about use that exceeded 
intended limits, another measure of impaired control. The remaining questions inquired about life-time 
and current problems (questions 9 and 11), as well as prior attempts at control (question 10) and 
intravenous drug use (question 12). 
Some of the drugs listed may have been prescribed by a doctor (such as amphetamines, sedatives or 
pain medications). If a participant reported the use of a prescription medication, interviewers 
determined if the drug was taken for reasons other than a doctor prescribed, or was taken more 
frequently or at higher doses than prescribed. Interviewers were instructed to code only those drugs 
that were 'abused', not those taken as prescribed for medical reasons. 
Reliability and feasibility studies 
The second stage of the project involved the following sequence of activities: (1) the training of at 
least two interviewers at each site to administer ASSIST 1.0; (2) the recruitment of approximately 25 
individuals per center who met inclusion and exclusion criteria; (3) the evaluation of instrument 
feasibility and test–retest reliability; and (4) further revision of the new drug screening instrument 
based on the study findings. 
The aims of the reliability study were: (1) to determine specific reliability of the preliminary items in 
order to make revisions in the content of the items, the length of the screening test, and the 
recommended response categories; and (2) to identify possible sources of response error in the 
instructions and format that required modification before a more systematic validity study could be 
conducted. 
The aim of the feasibility study was to evaluate the applicability and acceptability of the new 
screening procedure with different types of patients, in different settings, in different cultures, across a 
variety of substances. Patients and interviewers were asked to rate the proposed items in terms of 
their comprehensibility, cultural appropriateness and ability to elicit honest answers. Focus group 
exercises were also conducted at several sites. 
Research design 
Test–retest reliability is the comparison of ratings made during an initial interview, with independent 
ratings made in a second interview. The second interview (retest) was conducted by an interviewer 
blind to the results of the first interview. The period of time between the test and retest assessments 
was between one day and three days. To minimize practice effects and respondents' desire to 
provide identical information, the interviewer explained that during the second interview they should 
answer the questions directly and not attempt to recall their answers from the previous occasion. 
After the second (retest) interview was completed, the retest interviewer (or a third independent 
interviewer) asked the respondent to answer questions from a separate discrepancy interview that 
was designed to evaluate the feasibility of the ASSIST questions and procedures. The discrepancy 
interview began by reviewing with the respondent both the initial and second ratings on the 
designated items. If discrepancies occurred, the interviewer explored the reasons that gave rise to the 
discrepancy (in the respondent's view), and noted the respondent's responses to these questions. 
Following the discrepancy interview, the interviewer provided both qualitative and quantitative ratings 
of cultural appropriateness, comprehensibility and defensiveness. The latter ratings were designed to 
evaluate the potential bias associated with culturally sensitive questions. 
Collaborating sites were asked to conduct at least one focus group to explore several issues 
surrounding the use of screening tests in primary care in that particular country. Focus group 
participants included interviewers, investigators and research assistants. They were asked to 
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describe the reactions of different types of patients to the screening procedure, to comment on 
similarities and differences observed between samples, to provide their own subjective reactions to 
the procedures, to identify problems with administration of items and to evaluate the accuracy of the 
screening method. 
Translation and cultural adaptations 
Prior to subject recruitment, investigators at each site compiled a list of culture-specific names of 
common drugs of abuse in each country. The most commonly abused substances were listed for the 
country, as well as drugs most often associated with treatment and those most associated with legal 
problems. This information was used for the local adaptation of the drug classes (including colloquial 
names and examples) of the ASSIST screening interview used in the test–retest exercise. The study 
questionnaires, participant instructions, and response scales were translated into the local languages 
by at least two bilingual translators. After the materials were translated from English to the local 
language, any differences were discussed by the two translators. Corrections were made before the 
final translation was completed. 
Recruitment procedures 
Each collaborating center recruited approximately 25 volunteers. Forty per cent of the sample was 
recruited from general medical, primary care or community settings while the remaining participants 
were drawn from specialized alcohol and drug treatment services, primarily residential settings where 
patients could be reinterviewed conveniently several days later. A total of 236 sets of test–retest 
interviews were completed at the nine collaborating sites. Sites each contributed between 14 and 30 
sets of test–retest exercises. 
The rationale for these recruitment procedures was both practical and methodological. On the 
practical side, cross-national instrument development research is expensive and resource-intensive, 
which limited the number of subjects to the minimum required for adequate statistical power at the 
level of the total sample rather than at the individual site level. Drug treatment sites were chosen 
because they provide access to a population of drug users, and demonstrate ample variability across 
multiple substances in the frequency of substance use and related problems. The remaining sites 
were chosen to provide access to facilities where a range of substance users, particularly those with 
low and moderate levels of health risk, could be recruited to add variability to the measures under 
consideration. 
The following exclusion criteria were used to screen out inappropriate study participants: (1) 
communication difficulties (e.g. language problems, deafness); (2) cognitive impairment or mental 
retardation; (3) severe behavior disturbance, psychotic symptoms, uncooperativeness; (4) drug and 
alcohol intoxication or withdrawal; (5) likelihood that respondent would not be available for the second 
interview; and (6) age of respondent was under 18 or above 60. 
Interviewers 
Interviewers (2–4 per site) were selected on the basis of their familiarity with drugs of abuse. Seventy-
one per cent were female. Their average age was 32 years. They had approximately 15 years of 
education and many had advanced degrees (14% with Masters, 29% with PhDs, and 5% with MDs). 
One-fourth of the interviewers were working as researchers, one-third were employed primarily in the 
alcohol and drug treatment field and the remainder worked in medical, psychiatric or other facilities. 
 Characteristics of the sample 
Slightly over half of the sample (53.6%) was male and 33.7% were married or cohabiting. Sixty-one 
per cent of the participants were categorized as 'unemployed', including students (1.9%), 
homemakers (10.5%) and those with disabilities (4.8%). Twenty-five per cent of the sample were 
employed full time and another 14% were employed part-time. The mean age of the respondents was 
34 years. They had completed, on average, 10 years of education. Over half of the sample (59.7%) 
was recruited from alcohol and drug abuse treatment facilities while the remainder was drawn from 
general medical settings and psychiatric facilities.  
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 Data analysis 
The data were examined according to question stem (i.e. the main subject of the question, regardless 
of the type of substance), substance class and recruitment setting in order to provide 
recommendations for improving the ASSIST instrument. Qualitative data (the debriefing interview and 
results of the focus groups) were summarized by each center in English. Because of the small 
sample size and the study's focus on cross-national representativeness, site-specific analyses were 
not conducted. The analysis strategy consisted of: (1) computing kappa coefficients for each item in 
each drug class; (2) comparing average kappas across drugs to identify the most reliable items; (3) 
computing correlations between frequency of substance use (within each drug class) and the 
frequency of symptoms; (4) comparing internal consistency reliability coefficients (Cronbach's alphas) 
for the entire set of 11 items (excluding the life-time use question and the alcohol and tobacco drug 
classes); (5) examining the reduction in alpha if an item is deleted; (6) reviewing the qualitative data 
collected through the debriefing interview and focus groups with interviewers; (7) choosing eight items 
(referred to as ASSIST 2.0) on the basis of high kappas, high correlations with drug use frequency, 
strong item-total scale correlations, face validity, lack of overlap with other items and support from 
qualitative data. 
   
RESULTS 
  
Reliability 
On average, the time for administering the ASSIST 1.0 was 16 minutes, while the average retest time 
was 17.5 minutes. As expected, subjects recruited from alcohol and drug treatment facilities took 
significantly longer to complete the interview than subjects recruited from general medical settings 
(test time: 17.88 versus 13.26, t = 4.87, P < 0.001; retest time: 19.70 versus 14.33, t = 4.06, P < 
0.001). The average time between the test and retest interview was 2.16 days and ranged from 1.32 
in Sao Paulo to 3.28 in Harare. 
Test–retest coefficients of agreement (kappa-values) for both question stem and drug category are 
shown in Table 1. Prevalence rates for each drug category are noted in the first column of the table. 
Four categories (cannabis, cocaine, sedatives and opioids) had current prevalence rates ranging from 
23% (current use of cocaine) to 42% (current use of cannabis). These rates are sufficient to place 
confidence in the kappas. Drug classes with lower prevalence rates may have biased kappas, or 
coefficients may not have been computed at all. The table provides a summary of the test–retest 
analyses by averaging kappas across items and across substances. 
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Table 1   Test–retest kappa statistics by question and substance class (n=236).  
 ASSIST 1.0 Questions   
Substance 
class 
(prevalence  
rate, 
ever/current) 
Ever 
used  
 
Q1 
Used 
last  3 
months  
 
Q2 
Preoccupied  
 
Q3 
Worried  
 
Q4 
Problems  
 
Q5 
Neglect  
 
Q6 
Regrets  
 
Q7 
Used 
more  
 
Q8 
Concerns  
 
Q9 
Cut 
down  
 
Q10 
Troubled 
by  
problems  
 
Q11 
i.v. 
use  
 
Q12 
Average  
 
kappa 
(a) Tobacco 
products  
  (93.2/85.6) 0.97 0.95 0.67 0.64 0.50 0.24 0.51 0.53 0.77 0.68 0.58 (b) 0.64 
 
(b) Alcoholic 
beverages  
  (95.8/72.9) 
0.75 0.85 0.74 0.71 0.60 0.68 0.76 0.74 0.75 0.68 0.70 (b) 0.72 
(c) Cannabis  
  (76.7/42.4) 
0.95 0.76 0.72 0.66 0.52 0.64 0.43 0.58 0.63 0.54 0.58 (b) 0.64 
(d) Cocaine 
or crack  
  (41.9/22.9) 
0.96 0.75 0.72 0.73 0.73 0.67 0.64 0.72 0.79 0.74 0.77 0.94 0.76 
(e) Stimulants  
  (44.1/15.7) 
0.91 0.80 0.76 0.67 0.63 (a) 0.60 0.77 0.73 0.67 0.68 0.97 0.74 
(f) Inhalants  
  (18.6/2.5) 
0.91 0.72 0.80 (a) (a) (a) (a) 0.86 0.56 0.65 0.76 (b) (a) 
(g) Sedatives  
  (56.8/32.6) 
0.75 0.66 0.61 0.56 0.48 0.59 0.58 0.59 0.57 0.59 0.65 0.68 0.61 
(h) 
Hallucinogens  
  (36.0/5.5) 
0.96 (a) 0.53 0.33 (a) (a) (a) (a) 0.63 0.72 0.65 (b) (a) 
(i) Opioids  
  (55.9/39.4) 
0.94 0.83 0.77 0.82 0.80 0.76 0.61 0.64 0.81 0.78 0.79 0.84 0.78 
(j) Other 
drugs  
  (21.2/14.4) 
0.81 0.82 0.91 0.81 0.70 0.71 0.60 0.59 0.80 0.73 0.72 0.70 0.74 
Average 
kappa value 
for  drug 
classes c–j 
0.90 0.76 0.73 0.65 0.64 0.67 0.58 0.68 0.69 0.68 0.70 0.83  
 
a) = insufficient data to compute Kappa coefficients. (b) = Question does not apply to that substance 
 
The average kappas ranged from a high of 0.90 (consistency of reporting 'ever' use of 
substance) to a low of 0.58 (regretted what was done under influence of substance). In 
general, the reliabilities were in the range of good to excellent, with the following items 
demonstrating the highest kappas across all drug classes: Q.2 (use in the last 3 months, κ = 
0.76), Q.3 (preoccupied with drug use, κ = 0.73), Q.9 (concern expressed by others, κ = 
0.69), Q.11 (troubled by problems related to drug use, κ = 0.70) and Q.12 (i.v. drug use, κ = 
0.83). 
Using the discrepancy interview, information was obtained about the reasons for differences 
between test and retest answers, when they occurred. The most commonly mentioned 
explanations were respondent errors such as 'I didn't understand the question' (24%), 'I was 
not paying attention on one occasion' (18%), 'I couldn't remember the answer at the time' 
(15%), and 'I remembered this experience between interviews' (14%). Twenty-three per cent 
of the errors were attributed to interviewer error: 'My answers were not different. They seem 
to have been misunderstood by one of the interviewers' (13%) and 'one interviewer probed 
more than the other' (5%). 
The next set of analyses evaluated internal consistency reliability (alpha coefficients) and 
item correlations with current frequency of substance use. The results were used to identify 
items that contributed to the overall coherence of scales within each drug class. These 
analyses were conducted using the four drug categories with the highest prevalence rates 
and the most acceptable distributional properties (cannabis, cocaine, sedatives, opioids). 
The results are summarized in Table 2, along with the data from alcohol and tobacco. The 
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correlations are high for most items across all substances (except for tobacco). Because of 
the overlap in item content, it is not unexpected that the alpha coefficients for these scales 
are also high. The items, particularly those measuring social consequences, performed least 
well with respect to tobacco use. 
  
 Table 2   Alpha statistics and correlations ( r s) between symptom frequency and frequency 
of substance use within six substance classes.  
 Substance class 
Symptom 
Cannabis  
(n = 100) 
Cocaine  
(n = 54) 
Sedatives  
(n = 77) 
Opioids  
(n = 93) 
Tobacco  
(n = 202) 
Alcohol  
(n = 172) 
Preoccupiedar 0.74 0.51 0.58 0.70 0.37 0.59 
 
Worriedar 0.31 0.55 0.57 0.52 0.16 0.46 
Problemsar 0.37 0.52 0.38 0.65 0.07 0.42 
Neglectar 0.37 0.59 0.39 0.49 0.04 0.45 
Regretar 0.13 0.55 0.29 0.41 0.05 0.44 
More than intendedar 0.38 0.57 0.37 0.49 0.16 0.57 
Concernar 0.29 0.30 0.38 0.50 0.02 0.39 
Cut downbr 0.15 0.32 0.36 0.22 -0.03 0.41 
Troubledbr 0.30 0.54 0.30 0.31 0.08 0.38 
i.v. drug usebr (c) 0.28 0.20 -0.02 (c) (c) 
Alphad 0.85 0.91 0.87 0.85 0.73 0.92 
 
 a  Item rated on a five-point scale (0 = never, 1 = less than once a month, 2 = monthly, 3 = weekly, 4 = daily).  
 b  Item rated on a three-point scale (0 = no, never, 1= yes, but not in the past 3 months, 2 = yes, in the past 3 
months).  
 c  Not applicable.  
 d  Substance-specific internal consistency reliabilities (Cronbach's alphas) for the 10 candidate items.  
 
 
Feasibility data 
The debriefing interview, conducted at the end of the test–retest exercise, indicated that 
96% of the participants enjoyed being interviewed, and 81% thought that the length of the 
interview was 'just right'. A large majority (78%) of the respondents indicated that none of 
the questions were difficult to understand, and virtually all participants (98%) thought the 
questions were not offensive. In general, respondents had little difficulty understanding the 
questions and considered them to be appropriate. 
The debriefing interview also included two items recommended by Sudman & Bradburn 
(1982) to measure potential response bias in the context of a health survey. In general, the 
greater the perceived threat associated with a question, the greater the likelihood of denial 
or minimization. Perceived threat can be detected by projective questions asking 
respondents to estimate the discomfort and dishonesty 'other people' are likely to 
experience answering the same questions to which they have just responded. Respondents 
who report that a question would make 'most people' very uneasy are more likely to under-
report than other respondents are. Respondents who believe that other people are not likely 
to answer a question honestly are more likely to be dishonest themselves. Respondents 
were therefore asked to rate on a five-point scale how comfortable other people would be 
answering the ASSIST questions and how honest they thought other people would be. 
Table 3 shows that participants believed that 'most people' would be more comfortable 
answering questions about tobacco and alcohol (4.00 and 3.27, respectively, on a scale of 
1–5: 1 = very uncomfortable, 5 = very comfortable) than questions about cocaine and 
opioids (2.29 and 2.44, respectively).  
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 Table 3   Respondents' ( n =134) ratings of ASSIST questions in terms of discomfort likely 
to be experienced by others, a susceptibility to dishonest responding b and perceived 
importance of the screening information to their health care provider. c  
Substance 
Comforta 
X (SD) 
Honestyb 
X (SD) 
Importancec 
X (SD) 
 
Tobacco 4.00 (1.25) 3.74 (1.30) 4.64 (0.94) 
Alcohol 3.27 (1.41) 3.30 (1.30) 4.62 (0.96) 
Marijuana 3.03 (1.42) 2.81 (1.30) 4.51 (1.03) 
Cocaine 2.29 (1.43) 2.41 (1.26) 4.66 (0.90) 
Opioids 2.44 (1.42) 2.46 (1.27) 4.67 (0.87) 
Other substances 2.79 (1.34) 2.69 (1.23) 4.55 (0.96) 
 
 a  How comfortable are others answering this survey? (1 = very uncomfortable, 5 = very 
comfortable).  
 b  How honest are others when telling their health care provider about health habits? (1 = very 
honest, 5 = very dishonest).  
 c  How important is it that your health care provider know about your health habits? (1 = very 
uncomfortable, 5 = very comfortable).  
 
 
Three-way analysis of covariance was used to test the effects of substance class, 
recruitment site (primary care vs. drug treatment) and gender, using the respondent's age as 
a covariate. Site effects were not tested because of the small sample sizes. Table 3 shows 
that respondents rated some substances (e.g. tobacco) in the range of 'comfortable' (M = 
4.00), whereas other substances (e.g. cocaine) were rated more in the uncomfortable range 
(M = 2.29). There were significant differences across substances in the comfort ratings 
(F5.630 = 12.05, P < 0.001), and there was a significant substance by recruitment site 
interaction effect (F5,630 = 2.33, P < 0.05). General medical patients rated 'others' as being 
more comfort-able answering questions about alcohol and tobacco, whereas drug treatment 
patients rated others as being more comfortable with questions about marijuana and 
cocaine. The results were similar in response to a question asking 'how honest are others 
when telling their health care provider about' these substances. Respondents believed that 
'other people' would be most honest answering questions about tobacco and alcohol, and 
least honest about cocaine and heroin (F5,645 = 11.3, P < 0.001). Although there were no 
gender differences, respondents recruited from drug treatment settings had significantly 
higher honesty ratings than those recruited from primary care (F1,129 = 4.23, P < 0.05). 
Finally, participants were asked to rate how important it was for their health care provider to 
know about the substances listed in the ASSIST. Respondents rated all of the substances 
on average as very important for their provider to know about, with no significant differences 
by substance class, gender or recruitment site. 
Feasibility was also investigated by means of questions answered by each of the 
interviewers. The results indicated that the interviewers thought that participants were 
interested in the interview (97%), were not offended by the questions (100%), and were not 
responding in the negative to shorten the interview (95%). None of the interviewers 
perceived that participants were withholding information. Other questions asked interviewers 
to identify unclear or confusing items in the ASSIST. Comments were varied and covered a 
range of issues such as redundancy, vocabulary problems and time frame issues (e.g. 
confusion between 'last 3 months' versus 'life-time'). Two items, 'preoccupied with thoughts 
about using' and 'used more than intended', were identified as confusing. Seventy-seven per 
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cent of the interviewers indicated that the interview was 'easy' or 'very easy' to administer. 
Only 3% said that it was very difficult to conduct. 
Focus group exercises were conducted and site reports were completed to collect 
qualitative information on feasibility. Three sites (Adelaide, Sao Paulo and Beer Sheva) 
submitted focus group reports. Two reports identified problems with the instructions for 
'prescription drug use' versus 'abuse of drugs'. It was felt that these instructions should be 
placed at the beginning of the interview and should be clarified so that respondents do not 
include medical use of drugs when answering the screening questions. Some questions 
were felt to be too general or 'unfocused' (e.g. questions 3 and 4 'thoughts or concerns'). A 
suggestion was also made to clarify the frequency categories for the ASSIST items. 
Finally, a number of practical problems and logistical issues were identified during the 
reliability testing and data processing. A consistent problem was drug categorization. Each 
site was asked to create a culture-specific 'drug card' to list the primary drugs (e.g. valium, 
librium) for each major drug category (e.g. sedatives). The drug card should have listed the 
drugs most likely to be abused in that country, but may not necessarily have included every 
drug possibility. Drugs not listed as examples were consistently coded in the 'other' category 
when in some cases they should have been included in one of the primary categories. For 
example, there was confusion about where to list methadone. Another common problem 
was that prescription drug use was sometimes included as a drug of abuse even when the 
subject or interviewer noted that the drug was taken only as prescribed. 
Assist 2.0 
The reliability and feasibility data were used to revise and shorten the ASSIST. Two 
meetings of the investigators were held to coordinate the revision. The following criteria 
were applied in revising the instrument on the basis of the evidence obtained from the 
reliability and feasibility studies: (1) simplicity (the test should be brief and easy to apply in 
terms of its structure and format); (2) applicability (the test should be compatible with 
primary health care settings); (3) coverage of key domains (i.e. substance use, problems, 
dependence symptoms, i.v. use); (4) appropriateness for use with a range of people and 
problems (i.e. hazardous use; harmful use, dependence); and (5) compatibility with the 
empirical data (i.e. the items should have high internal consistency and test–retest 
reliability). 
Based on these guidelines, two types of modification were made. First, the length of the test 
was reduced to eight items. Based on a review of kappa coefficients, item-total correlations, 
distributional properties, qualitative feedback, correlation with other items, problems with 
language translations and coverage of relevant content domains, four items were dropped 
[items 4 (worried or concerned about own use); 7 (feelings of regret); 8 (used more than 
intended) and 11 (bothered by problems)]. Secondly, comprehension and coverage of some 
questions were improved. This was accomplished by: (1) changing the wording of three 
items; (2) revising the wording of response formats; (3) revising site adaptation procedures 
and instructions; (4) developing scoring procedures; and (5) retaining the structure and 
reference periods of the original test (life-time, 3 months). The revised questions are listed in 
Appendix I. These questions now form the basis for the screening questionnaire (ASSIST 
2.0) that can be used in further evaluation research. 
The final structure and scoring routines for the ASSIST will be derived from a subsequent 
international validation study. Given the acceptable face validity and distributional properties 
of the summary scores derived from ASSIST 1.0, it is probable that ASSIST 2.0 will permit 
the computation of the following measures: (1) life-time drug use (i.e. a count of the positive 
answers to question 1); (2) current substance use frequency (for each substance indicated 
in item 1, an estimate of the current frequency of use); (3) current substance-specific 
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severity (for each substance indicated in question 2, a sum of responses to questions 2–7 
provide an estimate of the degree of dependence and problems associated with that 
substance; and (4) injection drug use risk score (response to question 8). More complete 
information on the use and scoring of the ASSIST can be obtained from the WHO address 
provided at the end of this paper. 
DISCUSSION 
In psychological testing, reliability typically refers to the consistency of response to test 
items, and can be affected by the test item content, the person tested, the person 
undertaking the testing and the conditions under which the test is administered. The present 
study was concerned primarily with test item reliability, using a simple test–retest procedure 
to determine whether subjects would respond consistently to the same items when 
presented in an interview format on two different occasions. The analyses using kappa 
statistics gave evidence of high test–retest reliability, with some variability across drug 
classes and items. Internal consistency analyses suggested that the 11 original items were 
highly intercorrelated, but this was to be expected because of the overlap in content among 
some of the items. In general, these analyses suggest that reliability was acceptably high 
across all sites. 
Interviews with respondents suggested that the questions were not difficult to answer and 
were consistent with their expectations for a health interview. More importantly, there did not 
seem to be any confusion about the flow, format and structure of the interview. Most 
respondents had no criticisms or comments, and when problems occurred, they were 
caused by specific items and involved only small numbers of respondents. Nevertheless, 
there was some indication from the projective questions dealing with comfort and honesty 
(Table 3) that some respondents may perceive the drug questions to be threatening, and 
that they may minimize or deny drug use as a result. This finding suggests that further 
validation work on ASSIST 2.0 should be particularly attentive to the detection and 
minimization of response bias (Babor & Del Boca 1992). 
In general, qualitative data from the debriefing interview did not suggest that there were 
major problems associated with the administration of the ASSIST interview. Many problems 
mentioned in the open-ended comments were due to the large set of preliminary question 
stems that included redundant and overlapping items. This problem was resolved easily by 
reducing the number of items in the revised screening test. 
Comments provided by the interviewers corroborate these conclusions. The ASSIST items 
and format, despite some shortcomings, seemed to be feasible and appropriate, at least 
under research conditions. Concerns about length and redundancy were expected because 
the preliminary instrument was designed to be overly inclusive. 
The revised version of ASSIST (2.0) is now being released for further validation research 
and feasibility testing. ASSIST 2.0 is designed to be brief, flexible, comprehensive and 
appropriate for use in primary care. Although ASSIST 1.0 required approximately 13 
minutes, the revised version should take less than 5 minutes for most general practice 
patients because of the reduced item content and the addition of skipout instructions. 
Because ASSIST also screens for tobacco and alcohol use, this seems an acceptable 
amount of time to devote to risk factors that are not only likely to co-occur in the same 
individuals, but are also likely to require similar clinical interventions. 
Unlike other drug abuse screening tests, the ASSIST is designed to provide life-time, as well 
as current, estimates of substance-related risk. Screening with life-time questions like the 
Drug Abuse Screening Test or the CAGE-AID provides little information beyond the fact that 
the patient has used drugs sometime in the past. ASSIST 2.0 provides drug-specific 
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information about life-time use and current severity, which should be useful for health 
education and early intervention. The drug-specific information should also be useful when 
there is an opportunity to coordinate ASSIST data with biological screening results such as 
hair or urine analysis. 
Nevertheless, further validation research is necessary, especially in light of the limitations of 
the present study. First, the sample size was too small to permit more refined statistical 
analyses at the site level, and even with the data aggregated across samples, the numbers 
within certain drug categories were marginal or too small for analysis. Secondly, it was 
beyond the purpose of the present study to evaluate the concurrent and predictive validity of 
either ASSIST 1.0 or 2.0, which is a critical prerequisite to the eventual use of the test in 
primary care settings. The eight final items were selected on the basis of their association 
with drug use frequency, and not with ICD-10 dependence or harmful use. Thirdly, the 
preliminary version of ASSIST used in this investigation was not evaluated under typical 
conditions of primary care. Sixty per cent of the participants were patients in drug treatment 
settings, and only a small number of the interviewers were primary care health 
professionals. It is possible that ASSIST, even in its revised version, will prove to be less 
reliable and feasible under the routine clinical conditions of busy primary care practices. 
Finally, self-report screening tests such as ASSIST may be subject to additional response 
distortion in primary care settings when patients feel embarrassed, threatened or defensive 
about their substance use. 
Despite the challenges of research on substance abuse screening tests, there are clear 
benefits to the coordination of instrument development projects such as ASSIST across 
national boundaries. Most screening tests for drug abuse have been developed in the 
United States, where the drug use patterns, drug abuse problems and treatment responses 
differ significantly from other parts of the world. By developing a screening test in a multi-site 
international study, cross-cultural applicability is addressed at the design stage and 
feasibility problems are likely to be detected early and solved quickly because of the input 
available from diverse collaborators. Multi-site studies also have the advantage of expediting 
the design, evaluation and marketing of a new screening test, to the extent that the 
collaborating investigators are each capable of introducing the test and continuing its 
development within their own cultural and linguistic groups. 
In 1982, the World Health Organization initiated a program to develop an international 
screening test for hazardous and harmful alcohol use (Saunders et al. 1993). The program 
led to the creation of the Alcohol Use Disorders Identification Test (AUDIT), which has not 
only been found to be reliable and valid in numerous evaluation studies (Allen et al. 1997), 
but has also been used widely in primary care and other health settings throughout the 
world as part of screening and brief intervention programs (Ustun & Sartorius 1995; Babor & 
Higgins-Biddle 2000). The success of AUDIT raises the question of whether a similar 
international screening test could be developed for the detection of drug abuse. The results 
of this study suggest that a screening for drug abuse in the context of a more generic 
approach that includes alcohol and tobacco products is both reliable and feasible. Further 
research will be necessary to determine whether other prerequisites to a public health 
approach to secondary prevention are possible, specifically the collection of valid 
information free of response bias and the application of effective interventions to people at 
risk.  
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